PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 193 filers reported holding PDL BIOPHARMA INC in Q4 2016. The put-call ratio across all filers is 0.18 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $183,000 | -84.3% | 86,123 | -75.3% | 0.00% | -100.0% |
| Q3 2016 | $1,169,000 | -0.7% | 348,865 | -6.9% | 0.00% | 0.0% |
| Q2 2016 | $1,177,000 | -0.5% | 374,748 | +5.5% | 0.00% | 0.0% |
| Q1 2016 | $1,183,000 | +24.9% | 355,334 | +32.8% | 0.00% | 0.0% |
| Q4 2015 | $947,000 | -38.7% | 267,575 | -12.8% | 0.00% | -50.0% |
| Q3 2015 | $1,544,000 | -18.0% | 307,014 | +4.8% | 0.00% | 0.0% |
| Q2 2015 | $1,884,000 | -54.0% | 293,048 | -49.7% | 0.00% | -50.0% |
| Q1 2015 | $4,098,000 | +1.3% | 582,460 | +11.0% | 0.00% | 0.0% |
| Q4 2014 | $4,046,000 | -2.7% | 524,811 | -5.7% | 0.00% | 0.0% |
| Q3 2014 | $4,159,000 | -14.5% | 556,805 | +10.8% | 0.00% | -20.0% |
| Q2 2014 | $4,867,000 | +267.9% | 502,755 | +215.9% | 0.01% | +400.0% |
| Q1 2014 | $1,323,000 | -78.3% | 159,157 | -77.9% | 0.00% | -83.3% |
| Q4 2013 | $6,089,000 | -40.2% | 721,454 | -43.5% | 0.01% | -40.0% |
| Q3 2013 | $10,183,000 | +38.1% | 1,277,681 | +33.8% | 0.01% | +25.0% |
| Q2 2013 | $7,373,000 | – | 955,059 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Silver Point Capital L.P. | 23,783,273 | $58,745,000 | 6.82% |
| Park West Asset Management LLC | 14,397,212 | $35,561,000 | 0.74% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 633,700 | $1,565,000 | 0.24% |
| JBF Capital, Inc. | 543,990 | $1,344,000 | 0.22% |
| Context Capital Management, LLC | 465,172 | $1,149,000 | 0.16% |
| Bellecapital International Ltd. | 108,025 | $267,000 | 0.09% |
| FNY Investment Advisers, LLC | 100,000 | $247,000 | 0.07% |
| WINTON GROUP Ltd | 291,360 | $720,000 | 0.05% |
| Freedom Investment Management, Inc. | 54,735 | $135,000 | 0.02% |
| HANCOCK WHITNEY CORP | 187,757 | $464,000 | 0.02% |